Dallas, Texas (PRWEB) March 09, 2014
Rosellini Scientific, Inc. announced today that it has acquired a medical device portfolio from Medtronic consisting of six U.S. and eight International patents. The patents, which relate to remote monitoring of implantable medical devices, will be developed in companies spun-out of Rosellini Scientific, all of whom will have a focus on enhancing the delivery of digital medicine at the point of care. This includes combinations of remote monitoring and treatment, hospital inventory management and electronic medical record integration.
Commenting on the announcement, VP of Emerging Therapies Austin Duke, Ph.D., stated, "We will continue to focus on building a diversified portfolio of compelling patent assets in the implantable device space. Therapy is going to become more patient-centric and will increasingly be delivered point-of-care, as opposed to the confines of the large hospitals. We expect our product development path to continue to focus on smart, networked, implantable devices that change the standard of care in post-acute settings."
The Company has recently formed CardiaX, Inc. to develop the CardioPT™ device, which will serve as a comprehensive solution for patients with advanced heart failure, atrial fibrillation, and ventricular arrhythmias leading to sudden cardiac death. The technology has received nearly $2 million in development funding.
About Rosellini Scientific
Our focus begins in the hospital bed and follows the patient through their continuum of care. We support patients by preventing disease, restoring function and enhancing the quality of life. Our goal is to manage the medical devices designed to support patients in sub-acute healthcare settings. Where devices do not already exist, we invent them by developing solutions utilizing the interconnection of software, hardware and biomedical implants.
Visit http://www.roselliniscientific.com for more information.